Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
Pathos AI's $365M series D to fund trial of Novo tumor drug
Pathos AI has secured $365 million in series D funds as the biotech looks to fund trials of solid tumor drugs from Novo Nordisk and Prelude.
James Waldron
May 15, 2025 10:20am
Enliven calls time on phase 1 HER2 solid tumor program
May 15, 2025 7:50am
Takeda shoots down bispecifics bagged in Maverick buyout
May 8, 2025 8:30am
Relay starts 3rd layoff wave in one year, shedding 70 staffers
Apr 4, 2025 11:30am
BioNTech posts survival data behind bispecific's phase 3 push
Mar 28, 2025 8:00am
Servier pays $70M for Black Diamond's deprioritized cancer drug
Mar 19, 2025 7:53am
